Company intelligence / Profile preview

DeHydr8

Ownership: Private
Development stage: Other

Overview

DeHydr8's DehydraTECH platform, a self-emulsifying drug delivery system (SEDDS), has demonstrated significant bioavailability improvements for cannabinoids in clinical studies. In a randomized, placebo-controlled, double-blind study, the technology delivered over 300% more CBD to blood at the 30-minute mark compared to a control formulation[2]. Results suggest the technology delivered over 900% more CBD to the blood in the first 30 minutes compared to GW Pharmaceuticals' Epidiolex formulation on a concentration-adjusted basis[2].

Modalities: Drug delivery system
Industry: Biotech

Beyond the preview

Go deeper on DeHydr8.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DeHydr8.

Explore the full profile